CorMedix
CRMD
CorMedix (CRMD) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.29
- EPS estimate
- $0.24
- EPS surprise
- +21.85%
- Revenue surprise
- +6.13%
- Revenue
- $101.9M
- Revenue estimate
- $96.0M
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | $0.24 | $0.29 | +21.85% | $101.9M | SEC |
| Q1 2026 | May 14, 2026 | $0.34 | $0.43 | +25.40% | $127.4M | SEC |
| Q4 2025 | Mar 5, 2026 | $0.82 | $0.16 | −80.40% | $128.6M | SEC |
| Q3 2025 | Nov 12, 2025 | $0.63 | $1.26 | +98.64% | $104.3M | SEC |
| Q2 2025 | Aug 7, 2025 | $0.19 | $0.29 | +55.00% | $39.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.26 | $0.30 | +15.38% | $39.1M | SEC |
| Q4 2024 | Mar 25, 2025 | $0.13 | $0.22 | +67.05% | $31.2M | SEC |
| Q3 2024 | Oct 30, 2024 | −$0.12 | −$0.05 | +59.02% | $11.5M | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.25 | −$0.25 | +0.40% | $806,119.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.28 | −$0.25 | +9.71% | $0.00 | SEC |
| Q4 2023 | Mar 12, 2024 | −$0.20 | −$0.26 | −29.29% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.21 | −$0.17 | +19.05% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.24 | −$0.25 | −4.52% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.20 | −$0.24 | −19.46% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.19 | −$0.20 | −7.01% | $29,702.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$0.23 | −$0.17 | +26.09% | $6,817.00 | — |
| Q2 2022 | Aug 11, 2022 | −$0.21 | −$0.19 | +8.08% | $21,253.00 | — |
| Q1 2022 | May 12, 2022 | −$0.22 | −$0.18 | +18.18% | $7,636.00 | — |
| Q4 2021 | Mar 29, 2022 | −$0.23 | −$0.20 | +14.27% | $56,397.00 | — |
| Q3 2021 | Nov 9, 2021 | −$0.18 | −$0.22 | −24.50% | $38,088.00 | — |
Quarterly revenue
Frequently asked questions
When did CorMedix (CRMD) last report earnings?
CorMedix last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did CRMD beat earnings estimates?
Yes. CorMedix reported EPS of $0.29 for Q2 2026 against a $0.24 estimate — a 21.85% beat.
How much revenue did CRMD report last quarter?
CorMedix reported $101.9M in revenue for Q2 2026, against a consensus estimate of $96.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.